| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Everolimus | 159351-69-6 | sc-218452 sc-218452A | 5 mg 50 mg | $128.00 $638.00 | 7 | |
Everolimus is an mTOR (mammalian target of rapamycin) inhibitor. It may indirectly impact nephrocystin-2 through its effects on mTOR signaling pathways. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Sirolimus is another mTOR inhibitor similar to everolimus that has been studied for its potential to slow the progression of PKD by modulating mTOR-related pathways. | ||||||
13C6-Lys octreotide tri(trifluoroacetate) | 83150-76-9 (unlabeled free base) | sc-477942 | 500 µg | $388.00 | ||
Octreotide is a somatostatin analog that has been explored in some studies for its ability to inhibit cyst growth in PKD, although it does not directly target nephrocystin-2. | ||||||